Announced details
The Company was selected for a public offering program administered by the Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation and received a grant.
Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation. Other information, including location, representative, business activities, capital and year established, is not disclosed.
The Company will recognize ¥15 million as non-operating income in the fourth quarter of the fiscal year ending December 2026. This amount has already been incorporated into the full-year earnings forecast for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Three-dimensional stromal tissue, Functional Cellular Device (FCD®), Human 3D Mini-Liver®/Disease Model, 3D Mini-Intestinal Model |
| Counterparty | Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation |
| Counterparty overview | Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation. Other information, including location, representative, business activities, capital and year established, is not disclosed. |
| Relationship with the Company | The Company was selected for a public offering program administered by the Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation and received a grant. |
| Launch date | From December 2025 (actual: launch of sales of the Human 3D Mini-Liver®/Disease Model) |
| Applicable area | Development of new drugs for intractable fibrotic diseases, Drug efficacy evaluation, Development of novel therapeutics, Alternatives to animal testing |
| Impact on Business Performance | The Company will recognize ¥15 million as non-operating income in the fourth quarter of the fiscal year ending December 2026. This amount has already been incorporated into the full-year earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The grant amount of ¥15 million was finalized following completion of the prescribed project and receipt of the final grant award notice.